Literature DB >> 23943020

Priority of lymph node dissection for Siewert type II/III adenocarcinoma of the esophagogastric junction.

Shinichi Hasegawa1, Takaki Yoshikawa, Yasushi Rino, Takashi Oshima, Toru Aoyama, Tsutomu Hayashi, Tsutomu Sato, Norio Yukawa, Yoichi Kameda, Takeshi Sasaki, Hidetaka Ono, Kazuhito Tsuchida, Haruhiko Cho, Chikara Kunisaki, Munetaka Masuda, Akira Tsuburaya.   

Abstract

OBJECTIVE: The purpose of this study was to clarify the priority of nodal dissection in Siewert types II and III adenocarcinoma of the esophagogastric junction (AEG).
METHODS: The priority of nodal dissection was evaluated based on the therapeutic value index calculated by multiplying of the frequency of metastasis to each station and the 5-year survival rate of patients with metastasis to that station.
RESULTS: A total of 176 patients (95 type II and 81 type III) were examined. Among the lymph nodes that had a metastatic incidence exceeding 10 %, the stations showing the first to fourth highest index were the paracardial and lesser curvature nodes (Nos. 1, 2, and 3) and the node at the root of the left gastric artery (No. 7) in the total cohort, as well as in each type. The next station was the lower thoracic paraesophageal lymph node (No. 110), followed by the nodes along the proximal splenic artery (No. 11p) in type II, whereas it was the nodes along the proximal splenic artery (No. 11p) followed by the para-aortic nodes (No. 16a2), the nodes at the celiac artery (No. 9), and the nodes around the splenic hilum (No. 10) in type III.
CONCLUSIONS: These results suggest that the highest priority nodal stations to be dissected were the paracardial and lesser curvature nodes (Nos. 1, 2, and 3) and the nodes at the root of the left gastric artery (No. 7), regardless of the Siewert subtype, but the subsequent priority was different depending on the subtype.

Entities:  

Mesh:

Year:  2013        PMID: 23943020     DOI: 10.1245/s10434-013-3036-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

Review 1.  Lymphadenectomy: state of the art.

Authors:  Daniele Marrelli; Lorenzo De Franco; Livio Iudici; Karol Polom; Franco Roviello
Journal:  Transl Gastroenterol Hepatol       Date:  2017-01-17

2.  CD147 and MMP-9 expressions in type II/III adenocarcinoma of esophagogastric junction and their clinicopathological significances.

Authors:  Lei Huang; A-Man Xu; Qiang Peng
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Robotic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer.

Authors:  Kun Yang; Minah Cho; Chul Kyu Roh; Won Jun Seo; Seohee Choi; Taeil Son; Hyoung-Il Kim; Woo Jin Hyung
Journal:  Surg Endosc       Date:  2019-04-03       Impact factor: 4.584

4.  Adenocarcinoma of esophagogastric junction: controversial classification, surgical management, and clinicopathology.

Authors:  Lei Huang; A-Man Xu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

5.  Lymph node metastasis and lymphadenectomy of resectable adenocarcinoma of the esophagogastric junction.

Authors:  Xin-Zu Chen; Wei-Han Zhang; Jian-Kun Hu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

6.  Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.

Authors:  Jiang-Wei Xiao; Zi-Lin Liu; Peng-Cheng Ye; Ya-Jun Luo; Zhi-Ming Fu; Qin Zou; Shou-Jiang Wei
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

Review 7.  Western strategy for EGJ carcinoma.

Authors:  Simone Giacopuzzi; Maria Bencivenga; Jacopo Weindelmayer; Giuseppe Verlato; Giovanni de Manzoni
Journal:  Gastric Cancer       Date:  2016-12-30       Impact factor: 7.370

8.  Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction.

Authors:  Takaki Yoshikawa; Hiroya Takeuchi; Shinichi Hasegawa; Isao Nozaki; Kentaro Kishi; Seiji Ito; Masaki Ohi; Shinji Mine; Johji Hara; Tatsuo Matsuda; Naoki Hiki; Yukinori Kurokawa
Journal:  Gastric Cancer       Date:  2014-11-21       Impact factor: 7.370

Review 9.  Siewert III adenocarcinoma: treatment update.

Authors:  Alberto Di Leo; Andrea Zanoni
Journal:  Updates Surg       Date:  2017-03-16

10.  Should Splenic Hilar Lymph Nodes be Dissected for Siewert Type II and III Esophagogastric Junction Carcinoma Based on Tumor Diameter?: A Retrospective Database Analysis.

Authors:  Chen-Bin Lv; Chang-Ming Huang; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.